The Michael J. Fox Foundation has signed on to sponsor an early-stage study of a Parkinson's drug candidate in Sanofi's ($SNY) pipeline. In the pact, the foundation will own the data and results from the Phase Ib study of AVE 8112, a PDE4 inhibitor. And the two groups can decide how to proceed once they get the results in hand. For the foundation, it's a chance to push a new therapy up the pipeline. For Sanofi, it's a chance to gain some help from a partner, a major focus right now. Release